{"filings":[{"id":93013,"accession_number":"0001213900-26-052872","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"HeartSciences annual meeting approves director, stock plan, auditor; officer exculpation fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Andrew Simpson re-elected Class III director with 577,840 for, 107,738 withheld, 1,288,285 broker non-votes.","Amendment to 2023 Employee Stock Purchase Plan approved, increasing reserved shares to 1,250,000.","Proposal to amend certificate of formation for officer exculpation under Texas law did not pass; needed majority of outstanding shares.","Haskell & White LLP ratified as independent auditor for FY2026 with 1,872,912 votes for.","Adjournment proposal approved (1,784,662 for) to allow further proxy solicitation if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93012,"accession_number":"0001213900-26-040032","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"HeartSciences COO and Board Member Mark Hilz passes away at 67","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Hilz, COO, Corporate Secretary and Board member, died April 1, 2026 after an illness.","He served on the Board since 2013 and as COO/Secretary since March 2022.","Company will not hire a new COO; no changes expected to business or FDA clearance plans.","MyoVista wavECG 510(k) submission remains on track (submitted Dec 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104290,"accession_number":"0001437749-26-008420","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HeartSciences reports no FQ3 2026 revenue, cash at $3.4M; MyoVista platform advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["No revenue for FQ3 2026; cash and equivalents $3.4M, shareholders' equity $2.7M as of Jan 31.","MyoVista Insights platform got major upgrade March 13; deploying across health systems.","MyoVista wavECG device submitted to FDA for 510(k) clearance in Dec 2025.","Company expects key customer wins and initial revenues during 2026.","Management to host investor call after ACC meeting to demo platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":4319.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104289,"accession_number":"0001213900-26-005245","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"HeartSciences issues $3.6M 12% promissory note to Streeterville Capital, netting $3M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Company entered Note Purchase Agreement with Streeterville Capital for $3,605,000 promissory note, netting $3,000,000 after $600,000 OID and $5,000 expenses.","Note bears 12% annual interest and matures 18 months from January 13, 2026.","Streeterville may require monthly redemptions up to $405,000 starting six months after issuance; balance increases 5% if not reduced by $1.25M within 12 months.","Note contains customary covenants and events of default; upon default, interest accrues at up to 18% per annum.","Issued in unregistered private placement under Section 4(a)(2) of Securities Act, relying on accredited investor exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120585,"accession_number":"0001193125-25-320983","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"HeartSciences adopts standard indemnification agreements for directors and officers","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved form of Indemnification Agreement for all directors and executive officers on December 15, 2025.","Agreement provides indemnification to fullest extent under Texas law and advances expenses for proceedings.","Replaces prior indemnification arrangements; coverage continues under existing D&O insurance policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120584,"accession_number":"0001193125-25-319234","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HeartSciences reports no Q2 revenue, $2M cash; submits wavECG to FDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["No meaningful revenue for FQ2 2026; cash and equivalents $2.0M, shareholders' equity $4.2M as of Oct 31, 2025.","MyoVista wavECG device submitted to FDA for 510(k) clearance, a key regulatory milestone.","MyoVista Insights software platform (MDDS, exempt from 510(k)) launched May 2025; V1.1 released; commercial discussions underway.","Company plans investor call early 2026 to demonstrate MyoVista Insights software and provide commercialization strategy.","Algorithms for LVDD assessment separated from device submission due to updated ASE guidelines."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":4319.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120583,"accession_number":"0001213900-25-116128","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"HeartSciences amends equity plan to 1.25M shares, grants 70K restricted shares to CEO and RSUs to other officers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Amendment No. 3 to 2023 Equity Incentive Plan, increasing authorized shares from 1M to 1.25M plus annual evergreen.","CEO Andrew Simpson granted 70,000 restricted shares; COO Mark Hilz 45,000 RSUs; CFO Danielle Watson 15,000 RSUs; each non-employee director 15,000 RSUs.","Equity awards vest over 2-3 years with continued service; accelerated vesting if Company reaches $250K+ revenue in any future fiscal quarter.","Amendment and grants conditioned on shareholder approval of Plan Amendment at next annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120582,"accession_number":"0001193125-25-227023","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"HeartSciences extends loan maturity to 2026, raises $6.7M in Reg A, exchanges $2.06M debt for equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Loan maturity extended to Sept 30, 2026; accrued interest payment structure amended.","Raised $6.7M gross from Reg A offering of 1,912,383 Units as of Oct 1, 2025.","Converted 1,331,044 Series D Preferred shares into common stock under Reg A.","Exchanged $2.06M principal + $45K accrued interest for 597,578 common shares.","Common shares outstanding total 3,069,635 as of Oct 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137185,"accession_number":"0001193125-25-206295","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"HeartSciences regains Nasdaq minimum equity compliance; delisting risk cleared","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received formal notice on Sept 16, 2025 that it regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring minimum $2.5M stockholders' equity.","Previously disclosed non-compliance in March 2025; submitted a plan and received an extension from Nasdaq Staff.","The matter is now closed; no further action required regarding continued listing on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137184,"accession_number":"0001468492-25-000011","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HeartSciences reports Q1 FY2026 with $2.8M cash; launches MyoVista Insights platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No meaningful revenue for Q1 FY2026; cash and equivalents $2.8M, shareholders' equity $3.1M as of July 31, 2025.","Post-quarter raised $0.8M via Reg A+ and exchanged $0.7M debt into equity, strengthening balance sheet.","FDA granted Breakthrough Device designation for aortic stenosis ECG algorithm; now holds 44 granted patents.","Launched MyoVista Insights cloud-native platform; phased rollout began May 2025.","Separate FDA submissions planned for MyoVista wavECG device and algorithm, targeting clearances in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137183,"accession_number":"0001468492-25-000006","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HeartSciences raises $5.4M in Reg A offering, exchanges $1.8M debt for shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $5.4M gross proceeds from Reg A offering of units at $3.50; 1,556,409 units issued as of Sep 5, 2025.","Holders of 1,054,549 Series D Preferred shares converted to common stock as part of the offering.","Exchanged $1.805M unsecured promissory note for 506,348 common shares, reducing debt principal.","Total common shares outstanding: 2,654,540 as of Sep 5, 2025.","Each unit consists of one Series D Preferred share and a warrant to buy one common share at $5.00."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137182,"accession_number":"0001468492-25-000003","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HeartSciences raises $5.2M in Reg A offering and exchanges $1.655M debt for equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.2M from offering of 1,484,440 Units at $3.50/Unit as of Aug 22, 2025.","Each Unit consists of one Series D Preferred share and a warrant to buy one common share at $5.00.","Exchanged $1,655,000 of unsecured promissory note for 461,572 shares of common stock.","Common shares outstanding total 2,535,066 as of August 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137181,"accession_number":"0001213900-25-070889","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"HeartSciences increases ATM equity offering limit to $25M in amended distribution agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 3 to Equity Distribution Agreement raises maximum offering from $15M to $25M of common stock.","Commission rate: 4% on gross proceeds up to $11,036,310; 3% on excess.","Non-affiliate public float ~$14.7M; shelf sales limited to ~$4.9M per 12 months under S-3 I.B.6.","No shares sold under I.B.6 in prior 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137180,"accession_number":"0000950170-25-100335","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HeartSciences raises $4.3M in Reg A offering; exchanges $1.1M debt for equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4.3M from 1,241,188 units at $3.50/unit in Regulation A offering.","Holders of 850,981 Series D Preferred shares elected to convert into common stock.","Exchanged $1,105,000 of unsecured promissory note for 301,111 common shares.","Total common shares outstanding as of July 29, 2025: 2,244,247."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137179,"accession_number":"0000950170-25-098346","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HeartSciences reports no FY2025 revenue, $1.1M cash; advances MyoVista platform","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Zero revenue for fiscal year ended April 30, 2025; cash and equivalents $1.1M, shareholders' equity $0.2M.","Raised $3.1M gross in Reg A+ offering post-year-end; converted $0.9M debt to equity.","Launched MyoVista Insights cloud software platform in May 2025 at early adopter sites.","MyoVista wavECG device nearing FDA 510(k) submission; CMS approved $128/test reimbursement for AI-ECG algorithms.","FDA Breakthrough Device designation for aortic stenosis algorithm; 44 granted patents worldwide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137178,"accession_number":"0000950170-25-097293","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HeartSciences updates Regulation A offering: $2.8M raised, 797K units issued, 486K shares converted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $2.8M from 797,452 Units at $3.50/unit, each consisting of Series D Preferred and a warrant.","486,815 shares of Series D Preferred converted into common stock as of July 16, 2025.","Total common shares outstanding post-conversion: 1,797,914.","Offering maximum is $15M; remaining capacity available for future closings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137177,"accession_number":"0001213900-25-063491","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"HeartSciences expands equity plan to 1M shares, grants RSUs and options tied to FDA clearance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to 2023 Equity Incentive Plan increasing maximum shares to 1,000,000; subject to shareholder vote at next annual meeting.","CEO Andrew Simpson received 68,750 RSUs; COO Mark Hilz received 56,250 RSUs; vest upon FDA clearance of MyoVista Device or Change of Control.","Granted options: CEO 275,000, COO 225,000, CFO 25,000 at $4.37/share, vesting over three years with acceleration on FDA clearance.","Non-employee directors each received 25,000 options at $4.37.","As of July 11, 2025, raised $1.7M from Reg A offering (487,701 units) and exchanged $855K debt for 233,229 shares; total shares outstanding ~1.555M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137176,"accession_number":"0001213900-25-060467","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"HeartSciences amends bylaws to add jury waiver, 3% derivative threshold","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Adds jury trial waiver for 'internal entity claims' under Texas Business Organizations Code.","Requires 3% ownership threshold for shareholders to initiate derivative proceedings.","Technical revisions to clarify exclusive forum provision.","Amendments effective June 27, 2025, filed as Exhibit 3.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154471,"accession_number":"0000950170-25-081410","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HeartSciences gets FDA Breakthrough Device designation for AI-ECG algorithm detecting aortic stenosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Device designation for HeartSciences' Aortic Stenosis AI-ECG algorithm.","Algorithm detects moderate-to-severe aortic stenosis via MyoVista Insights cloud platform integrated with EHR.","Trained on >120,000 ECG records; can detect AS up to 24 months before echocardiography.","No additional hardware required; uses existing ECG data for real-time or retrospective analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154470,"accession_number":"0000950170-25-081197","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"HeartSciences launches $15M offering of Series D Preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Placement Agent Agreement with Digital Offering LLC for best-efforts offering of up to 4,285,714 Units at $3.50 each.","Each Unit consists of one share of Series D Preferred Stock and a warrant to buy common at $5.00 per share.","Placement agent receives 7% cash fee and 3% warrant coverage (Agent Unit Warrants at $4.375).","Certificate of Designations for Series D Preferred Stock filed with Texas Secretary of State effective May 21, 2025.","Offering registered on Form 1-A, qualified by SEC on March 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154469,"accession_number":"0000950170-25-080578","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HeartSciences granted foundational US patent for ECG-based heart function assessment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO granted patent covering estimation of heart function measures via ECG; critical for early detection of heart disease.","HeartSciences now holds 10 US patents and 34 international patents (44 total), including China, India, and key European markets.","CEO Andrew Simpson says patent reinforces company's position in the AI-ECG field and embedded IP value.","Patent further expands HeartSciences’ AI-ECG algorithm portfolio for transforming ECGs to enable earlier detection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154468,"accession_number":"0000950170-25-078404","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"HeartSciences files Certificate of Designations for Series D Preferred Stock in $15M offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Designates 4,285,714 shares of Series D Convertible Preferred Stock for the Unit offering (each Unit: one Series D share + warrant to buy common at $5.00).","Each Series D share convertible into one common share at holder's option.","No dividends; perpetual, non-redeemable, ranks senior to common on liquidation rights.","Company may force conversion upon change in control, common stock ≥$5.00 for 10 days, or $15M underwritten offering.","Liquidation preference of $3.50 per share plus unpaid dividends before junior securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154467,"accession_number":"0000950170-25-074598","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Nasdaq grants HeartSciences extension to Sept 15, 2025 for equity rule; Q3 cash $2.6M, equity $1.8M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq extension to Sept 15, 2025 to regain $2.5M minimum stockholders' equity; delisting if not met by Oct 31, 2025 10-Q filing.","Q3 FY2025 ended Jan 31, 2025: no revenue, cash $2.6M, shareholders' equity $1.8M.","MyoVista wavECG device clinical validation nearing completion; FDA submission expected first half calendar 2025.","Low ejection fraction algorithm pre-validation with Rutgers; aim for FDA submission in second half 2025.","CMS 2025 OPPS final rule includes AI-ECG reimbursement effective Jan 2025, enabling payment upon commercial launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173028,"accession_number":"0001013762-25-001087","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"HeartSciences receives Nasdaq delisting notice over $1.79M equity vs $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on March 19, 2025: stockholders' equity of $1.79M below $2.5M minimum.","Has 45 calendar days, until May 5, 2025, to submit a plan to regain compliance.","If plan accepted, Nasdaq may grant up to 180 days from March 19 to cure; no assurance.","Failure could lead to suspension/delisting, harming liquidity, market price, and financing ability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173027,"accession_number":"0000950170-25-038762","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HeartSciences Q3 FY2025 no revenue, cash $2.6M; FDA submission for MyoVista device expected H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["No revenue for Q3 FY2025; cash and equivalents $2.6M, shareholders' equity $1.8M as of Jan 31, 2025.","Final pre-submission meeting with FDA for MyoVista wavECG device completed Feb 2025; clinical validation within weeks, FDA submission targeted H1 2025.","MyoVista Insights cloud platform Phase 1 completed Dec 2024; Phase 2 (AI-ECG reporting, subject to FDA clearance) targets submission H2 2025.","Pre-validation work commenced with Rutgers on low ejection fraction algorithm licensed from Mount Sinai; aim for FDA submission H2 2025.","CMS 2025 OPPS final rule includes AI-ECG reimbursement effective Jan 2025, enabling reimbursement upon commercial launch."],"consensus_eps_estimate":-1.938,"consensus_eps_actual":-7.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173026,"accession_number":"0000950170-25-007314","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"HeartSciences grants 117K options to execs and directors at $3.33 strike","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Andrew Simpson and COO Mark Hilz each receive 45,000 options; CFO Danielle Watson receives 9,000.","Non-employee directors Brian Szymczak, Bruce Brent, and David R. Wells each receive 6,000 options.","All options have exercise price of $3.33 per share; executive options vest over 3 years with 1-year cliff.","Director options vested 1/4 immediately, remainder quarterly; vesting may accelerate on FDA clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190050,"accession_number":"0001213900-24-109832","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"HeartSciences withdraws S-1 registration statement for proposed public offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Withdrew Registration Statement on Form S-1 filed June 7, 2023 (as amended).","No securities were sold; registration statement was never declared effective by SEC.","Company preserving flexibility to explore other financing sources; offering not being pursued at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190049,"accession_number":"0000950170-24-136647","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HeartSciences reports Q2 FY2025 zero revenue; cash $4.1M; MyoVista device on track for FDA submission Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["No revenue in Q2 FY2025; cash and equivalents $4.1M, shareholders' equity ~$4.0M at Oct 31, 2024.","MyoVista wav ECG device on track for FDA submission around Q1 2025; final pre-submission meeting with FDA requested.","MyoVista Insights Phase 1 (no regulatory clearance) completion by end of 2024; test sites targeted H1 2025. Phase 2 AI-ECG clearance target H2 2025.","Pre-validation of Mount Sinai-licensed low ejection fraction AI-ECG algorithm progressing; CMS 2025 OPPS final rule includes reimbursement path."],"consensus_eps_estimate":-2.295,"consensus_eps_actual":-4.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190048,"accession_number":"0000950170-24-124132","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"HeartSciences stockholders ratify auditor and approve adjournment at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ratified Haskell & White LLP as auditor for FY2025: 413,499 for, 9,896 against, 1,116 abstain.","Approved adjournment proposal to solicit additional proxies: 367,736 for, 18,963 against, 37,811 abstain.","No other matters were considered or voted upon at the November 7, 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190047,"accession_number":"0001213900-24-089344","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K/A","filed_at":"2024-10-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Heart Test Laboratories officially changes name to HeartSciences Inc.; Nasdaq trading starts Oct 23","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Name change from Heart Test Laboratories, Inc. to HeartSciences Inc. effective Oct 11, 2024, confirmed by Texas Secretary of State.","Shareholders approved the name change at the Jan 17, 2024 annual meeting.","Trading under new name on Nasdaq begins at market open Oct 23, 2024; tickers HSCS/HSCSW unchanged.","No changes to CUSIP numbers, outstanding shares, or warrant certificates as a result of the name change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190046,"accession_number":"0001213900-24-088995","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Heart Test Laboratories files to change corporate name to HeartSciences Inc.; ticker symbols unchanged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment with Texas on October 11, 2024 to change name to HeartSciences Inc.","Name change approved by shareholders at Annual Meeting held January 17, 2024.","Awaiting confirmation from Texas Secretary of State; effective date to be announced separately.","Ticker symbols HSCS and HSCSW and CUSIP numbers remain unchanged; stock certificates unaffected.","No other changes to the Amended and Restated Certificate of Formation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.33,"calibrated_materiality_score":0.33,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206551,"accession_number":"0000950170-24-105923","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HeartSciences reports Q1 FY2025 cash of $4.3M, raises $1.9M in non-dilutive debt; MyoVista device on track","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and cash equivalents of $4.3M as of July 31, 2024; shareholders' equity of $5.9M.","Subsequent to quarter end, closed $1.9M net non-dilutive 18-month loan and extended $500K loan to Sep 2025.","FDA 510(k) submission for MyoVista wavECG device remains on track for Q1 calendar 2025.","Cloud-based MyoVista Insights platform Phase 1 on track for end of calendar 2024; FDA submission target H2 2025.","No revenue reported for Q1 FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206550,"accession_number":"0000950170-24-105155","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Heart Test Laboratories enters $2.51M note purchase agreement with Streeterville Capital, net proceeds $1.86M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $2.51M unsecured promissory note to Streeterville Capital; 8.5% interest, 18-month maturity, $500K OID.","Net proceeds of $1.86M after OID and $10K transaction expenses; used for general working capital.","Monthly redemption cap of $270K starting March 2025; balance increases 5% if not reduced by $900K by Sept 2025.","Placement agents Maxim Group and Ascendiant Capital received 7% commission on gross proceeds.","Note sold in unregistered transaction relying on Section 4(2) exemption; HSCS listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206549,"accession_number":"0000950170-24-099524","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Heart Test Labs extends $500k loan maturity to Sep 2025; accelerates interest payments","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $500,000 at 12% compounded annually; maturity extended from Sep 30, 2024 to Sep 30, 2025.","Accrued interest must be paid within 5 business days of Aug 19, 2024 and again on Sep 30, 2024.","Company may prepay any amount ≥$50,000, applied first to interest then principal.","Company releases Front Range from all claims arising up to date of amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206548,"accession_number":"0001013762-24-002081","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HeartSciences reports FY2024 cash of $5.8M; cloud-platform beta and FDA timeline updates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $5.8M; shareholders' equity $7.3M as of April 30, 2024.","Net proceeds of $10.3M from stock sales; $1.1M debt converted to equity.","Issued common stock to Mount Sinai for algorithm licenses, recognizing $1.6M intangible asset.","MyoVista Insights cloud-platform beta completed; FDA submission targeted for mid-2025.","MyoVista wav ECG device FDA submission expected in Q1 2025 after final testing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223721,"accession_number":"0001213900-24-049670","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HeartSciences regains Nasdaq minimum bid price compliance; hearing cancelled","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified HeartSciences on June 3, 2024 that it regained compliance with $1.00 minimum bid price requirement.","Company met the requirement on May 31, 2024 after 10 consecutive trading days with closing bid price over $1.00.","Previously notified of non-compliance on August 2, 2023; scheduled June 27, 2024 hearing cancelled.","Common stock (HSCS) and warrants (HSCSW) continue listing on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223720,"accession_number":"0000950170-24-063494","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Heart Test Labs obtains temporary stay of Nasdaq delisting; hearing set for June 27","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq delisting action stayed pending oral hearing on June 27, 2024.","Company implemented 1-for-100 reverse stock split on May 17, 2024.","Previously, stock closed at $0.10 or less for 10 consecutive days triggering Low Priced Stocks Rule.","Company intends to argue it has regained compliance with Minimum Bid Price and Low Priced Stocks Rules.","No assurance of successful appeal; shares continue trading under HSCS and HSCSW pending outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223717,"accession_number":"0001213900-24-044136","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K/A","filed_at":"2024-05-16T23:59:59+00:00","items":["3.03","5.03"],"status":"ready","headline":"Heart Test Laboratories files 8-K/A to clarify reverse stock split and warrant adjustments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Heart Test Laboratories filed Amendment No. 1 to Form 8-K to clarify details of its 1-for-100 reverse stock split.","The reverse stock split affects both common stock and warrants, with split-adjusted trading expected at market open on May 17, 2024.","The exercise price of public warrants will be proportionately increased to $425.00 per share post-split.","The CUSIP for common stock changes to 42254E302; trading symbols HSCS and HSCSW remain unchanged.","Equitable adjustments to outstanding warrants ensure every 100 pre-split shares become 1 post-split share upon exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223719,"accession_number":"0001213900-24-043196","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["3.03","5.03"],"status":"ready","headline":"Heart Test Laboratories to effect 1-for-100 reverse stock split on May 17, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split of common stock and warrants at 1-for-100 ratio, effective at market open on May 17, 2024.","Post-split CUSIP for common stock is 42254E302; trading symbols HSCS and HSCSW unchanged.","Warrant exercise price adjusted proportionally to $425.00 per share; fractional shares rounded up.","Adjustments to outstanding warrants ensure equitable conversion for holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223718,"accession_number":"0001213900-24-041736","cik":1468492,"company_name":"HeartSciences Inc.","ticker":"HSCS","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["3.01","3.03","5.03","9.01"],"status":"ready","headline":"Nasdaq staff determination to delist Heart Test Laboratories; company plans appeal and 1-for-100 reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq staff determination to delist under Low Priced Stocks Rule (closing bid ≤$0.10 for 10 consecutive days).","Company intends to appeal by May 16, 2024; hearing will stay delisting pending Panel decision.","Board filed Certificate of Amendment for a 1-for-100 reverse stock split to regain compliance.","Reverse split also adjusts warrants; exercise price changes to $425.00 per share.","Shareholders approved split at Jan 2024 annual meeting; board selected 1-for-100 ratio on May 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5732460.000000001,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}